R-baclofen reverses a social behavior deficit and elevated protein synthesis in a mouse model of fragile X syndrome

International Journal of Neuropsychopharmacology

Volumn 18, Issue 9, 2015, Pages 1-13

  Qin, Mei ^a   Huang, Tianjian ^a   Kader, Michael ^a   Krych, Leland ^a   Xia, Zengyan ^a   Burlin, Thomas ^a   Zeidler, Zachary ^a   Zhao, Tingrui ^a   Smith, Carolyn B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Fragile X syndrome; MTOR; Protein synthesis; R baclofen; Social behavior

Indexed keywords

ARBACLOFEN; BRAIN PROTEIN; GLUCOSE; INITIATION FACTOR 4E BINDING PROTEIN 1; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; S6K1 PROTEIN; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; FMR1 PROTEIN, MOUSE; FRAGILE X MENTAL RETARDATION PROTEIN; MTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; COMPARATIVE STUDY; CONTROLLED STUDY; DORSAL HIPPOCAMPUS; ENZYME ACTIVITY; FRAGILE X SYNDROME; FRONTAL CORTEX; GENOTYPE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HYPERACTIVITY; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SOCIAL BEHAVIOR; SOCIAL BEHAVIOR DEFICIT; SYNAPTOSOME; UPREGULATION; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; FRONTAL LOBE; KNOCKOUT MOUSE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BACLOFEN; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; FRONTAL LOBE; GABA-B RECEPTOR AGONISTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; TOR SERINE-THREONINE KINASES;

EID: 84948004803     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv034     Document Type: Article

References (31)

1. Bear MF, Huber KM, Warren S.T. (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370-377.
2. Berry-Kravis E.M., Hessl D, Rathmell B., Zarevics P, Cherubini M, Walton-Bowen K, Mu Y., Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter R.L., Bear MF, Hagerman R.J. (2012) Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 4:152ra127.
3. Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, Murphy J.P., Pierre P., Klann E. (2012) Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76:325-337.
4. D'Hulst C., Kooy R.F. (2007) The GABAA receptor: a novel target for treatment of fragile X? Trends Neurosci 30:425-431.
5. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser C.E., Stone EF, Chen C, Fak JJ, Chi S.W., Licatalosi DD, Richter JD, Darnell R.B. (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146:247-261.
6. Giuffrida R, Musumeci S, D'Antoni S, Bonaccorso CM, Giuffrida-Stella AM, Oostra B.A., Catania M.V. (2005) A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J Neurosci 25:8908-8916.
7. Gürtler A., Kunz N, Gomolka M., Hornhardt S, Friedl AA, McDonald K, Kohn J.E., Posch A. (2013) Stain-Free technology as a normalization tool in Western blot analysis. Anal Biochem 433:105-111.
8. Hagerman RJ, Berry-Kravis E, Kaufmann W.E., Ono MY, Tartaglia N, Lachiewicz A, Kronk R., Delahunty C, Hessl D, Visootsak J., Picker J, Gane L, Tranfaglia M. (2009) Advances in the treatment of fragile X syndrome. Pediatr 123:378-390.
9. Heitzer AM, Roth AK, Nawrocki L, Wrenn C.C., Valdovinos M.G. (2013) Brief report: Altered social behavior in isolation-reared Fmr1 knockout mice. J Autism Dev Disord 43:1452-1458.
10. Henderson C, Wijetunge L, Kinoshi M.N., Shumway M., Hammond RS, Postma FR, Brynczka C, Rush R., Thomas A, Paylor R, Warren S.T., Vanderklish PW, Kind PC, Carpenter RL, Bear M.F., Healy A.M. (2012) Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med 4:152ra128.
11. Huber KM, Gallagher SM, Warren S.T., Bear M.F. (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99:7746-7750.
12. Isaacson JS, Hille B. (1997) GABA(B)-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons. Neuron 18:143-152.
13. Javitt DC, Schoepp D, Kalivas P.W., Volkow ND, Zarate C, Merchant K, Bear M.F., Umbricht D., Hajos M, Potter WZ, Lee C.M. (2011) Translating glutamate: from pathophysiology to treatment. Sci Transl Med 3:102mr2.
14. Jaworski J, Sheng M. (2006) The growing role of mTOR in neuronal development and plasticity. Mol Neurobiol 34:205-219.
15. Liu ZH, Smith C.B. (2009) Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome. Neurosci Lett 454:62-66.
16. Liu ZH, Chuang DM, Smith C.B. (2011) Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychop 14:618-630.
17. Liu ZH, Huang T, Smith C.B. (2012) Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome. Neurobiol Dis 45:1145-1152.
18. Lüscher C., Jan LY, Stoffel M, Malenka R.C., Nicoll R.A. (1997) G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron 19:687-695.
19. Michalon A, Sidorov M, Ballard T.M., Ozmen L., Spooren W, Wettstein JG, Jaeschke G, Bear M.F., Lindemann L. (2012) Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74:49-56.
20. Mines MA, Yuskaitis CJ, King M.K., Beurel E., Jope R.S. (2010) GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLOS ONE 5: e9706.
21. Oostra BA, Willemsen R. (2003) A fragile balance: FMR1 expression levels. Hum Mol Gen 12(2):R249-R257.
22. Osterweil EK, Krueger DD, Reinhold K, Bear M.F. (2010) Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 30:15616-15627.
23. Pacey LK, Tharmalingam S, Hampson D.R. (2011) Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome. J Pharm Exp Ther 338:897-905.
24. Paxinos G, Frankin KBJ (2001) The mouse brain in stereotaxic coordinates. New York: Academic Press.
25. Peier AM, McIlwain KL, Kenneson A, Warren S.T., Paylor R., Nelson, DL (2000) (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Gen 9:1145-1159.
26. Qin M, Kang J, Smith C.B. (2002) Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99:15758-15763.
27. Qin M, Kang J, Burlin T V, Jiang C, Smith C.B. (2005a) Post-adolescent changes in regional cerebral protein synthesis: An in vivo study in the Fmr1 null mouse. J Neurosci 25:5087-5095.
28. Qin M, Kang J, Smith C.B. (2005b) A null mutation for Fmr1 in female mice: Effects on regional cerebral metabolic rate for glucose and relationship to behavior. Neuroscience 135:999-1009.
29. Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T., McBride SM, Klann E, Zukin R.S. (2010) Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 30:694-702.
30. Smith CB, Deibler GE, Eng N, Schmidt K., Sokoloff L. (1988) Measurement of local cerebral protein synthesis in vivo: influence of recycling of amino acids derived from protein degradation. Proc Natl Acad Sci USA 85:9341-9345.
31. Vigot R, Barbieri S, Bräuner-Osborne H, Turecek R, Shigemoto R, Zhang YP, Luján R, Jacobson LH, Biermann B, Fritschy JM, Vacher CM, Müller M, Sansig G, Guetg N, Cryan JF, Kaupmann K, Gassmann M, Oertner TG, Bettler B (2006) Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron 50:589-601.